This study compares the haemodynamic and hormonal responses during haemorrhage of conscious dogs pre-treated with an endothelin-A (ET-A) receptor inhibitor. The dogs were studied in two different randomized groups: the control group and a group that was given the ET-A receptor antagonist ABT-627 (as a bolus of 1mg·kg of body weight-1 followed by 0.01mg·kg body weight-1·min-1 intravenously). The time-course was the same for both groups: after a 1h baseline period (pre-haemorrhage), blood (25ml·kg of body weight-1) was withdrawn within 5min. Haemodynamics were continuously recorded and hormone levels measured after 1h (post-haemorrhage). Thereafter, the blood withdrawn was retransfused within 5min and haemodynamics again observed for 1h (post-retransfusion). In ABT-627-treated dogs, the decrease in mean arterial pressure from 87±3 to 64±3mmHg (P<0.05 versus pre-haemorrhage), and cardiac output from 2.1±0.1 to 1.3±0.1l·min-1 (P<0.05 versus pre-haemorrhage) and the increase in systemic vascular resistance from 3286±174 to 4211±230dyn·s·cm-5 (P<0.05 versus pre-haemorrhage) during acute haemorrhage are comparable with controls. During haemorrhage in controls, vasopressin levels increased from 0±0 to 13±2pg·ml-1 (P<0.05 versus pre-haemorrhage), angiotensin II levels increased from 9±1 to 28±9pg·ml-1 (P<0.05 versus pre-haemorrhage) and adrenaline levels increased from 134±22 to 426±74pg·ml-1 (P<0.05 versus pre-haemorrhage) whereas noradrenaline levels did not change (approx. 200 pg·ml-1). In ABT-627-treated dogs, vasopressin levels increased from 0.2±0.0 to 22.2±6.1pg·ml-1 (P<0.05 versus pre-haemorrhage and P<0.05 versus control), angiotensin II levels increased from 8±1 to 37±8pg·ml-1 (P<0.05 versus pre-haemorrhage), noradrenaline levels increased from 147±16 to 405±116pg·ml-1 (P<0.05 versus pre-haemorrhage) and adrenaline levels did not change (200 pg·ml-1) during haemorrhage. We conclude from our results that dogs receiving the selective ET-A inhibitor ABT-627 seem to show a different hormonal response after haemorrhage compared with controls, displaying considerably higher noradrenaline concentrations. Independent of ET-A receptor inhibition, cardiac output during haemorrhage was maintained within the control range. This may indicate that the organism is defending blood flow (cardiac output) over blood pressure during haemorrhage, and that this defence strategy is not compromised by ET-A receptor inhibition.
Skip Nav Destination
Article navigation
September 2002
-
Cover Image
Cover Image
Conference Article|
September 01 2002
Haemodynamic and hormonal changes during haemorrhage in conscious dogs treated with an endothelin-A receptor antagonist
Claudia HÖHNE;
1Experimental Anaesthesia, Clinic of Anaesthesiology and Surgical Intensive Care Medicine, Campus Virchow-Klinikum, Charité, Augustenburger Platz 1, D-13353 Berlin, Germany
Dr C. Höhne (e-mail [email protected]).
Search for other works by this author on:
Roland C.E. FRANCIS;
Roland C.E. FRANCIS
1Experimental Anaesthesia, Clinic of Anaesthesiology and Surgical Intensive Care Medicine, Campus Virchow-Klinikum, Charité, Augustenburger Platz 1, D-13353 Berlin, Germany
Search for other works by this author on:
Gabriele KACZMARCZYK;
Gabriele KACZMARCZYK
1Experimental Anaesthesia, Clinic of Anaesthesiology and Surgical Intensive Care Medicine, Campus Virchow-Klinikum, Charité, Augustenburger Platz 1, D-13353 Berlin, Germany
Search for other works by this author on:
Willehad BOEMKE
Willehad BOEMKE
1Experimental Anaesthesia, Clinic of Anaesthesiology and Surgical Intensive Care Medicine, Campus Virchow-Klinikum, Charité, Augustenburger Platz 1, D-13353 Berlin, Germany
Search for other works by this author on:
Publisher: Portland Press Ltd
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© 2002 The Biochemical Society and the Medical Research Society
2002
Clin Sci (Lond) (2002) 103 (s2002): 336S–339S.
Citation
Claudia HÖHNE, Roland C.E. FRANCIS, Gabriele KACZMARCZYK, Willehad BOEMKE; Haemodynamic and hormonal changes during haemorrhage in conscious dogs treated with an endothelin-A receptor antagonist. Clin Sci (Lond) 1 September 2002; 103 (s2002): 336S–339S. doi: https://doi.org/10.1042/CS103S336S
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.